Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20328914 | 1.00 | EGLN1 (0.44) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL17305900 | 0.93 | EGLN1 (0.48) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL17996825 | 0.93 | EGLN1 (0.48) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL7492912 | 0.91 | EGLN1 (0.41) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL17888434 | 0.87 | EGLN1 (0.45) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL1331195 | 0.87 | EGLN1 (0.45) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL30191547 | 0.85 | EGLN1 (0.46) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL14220359 | 0.85 | EGLN1 (0.46) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL20962674 | 0.84 | EGLN1 (0.43) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 | |
| SCHEMBL16418300 | 0.84 | EGLN1 (0.45) | EGLN1ALDH1A1POLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150705-B2 | Curing liquids | OMG ADDITIVES LIMITED (GB) | 2015-10-06 | — | — | US | claimed |
| EP-2521750-B1 | CURING LIQUIDS | OMG UK TECHNOLOGY LTD (GB) | 2014-07-02 | — | — | EP | claimed |
| US-20130123452-A1 | CURING LIQUIDS | OMG ADDITIVES LIMITED (UK) | 2013-05-16 | — | — | US | claimed |
| EP-2343336-A1 | Curing liquids | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2011-07-13 | — | — | EP | claimed |
| EP-2038356-B1 | LIQUID HARDENING | UNILEVER PLC (GB) | 2010-08-11 | — | — | EP | claimed |
| US-20090253833-A1 | Liquid Hardening | OMG UK TECHNOLOGY LTD (GB) | 2009-10-08 | — | — | US | claimed |
| US-6646122-B1 | Triazacyclohenonane ligand | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-11-11 | — | — | US | claimed |
| EP-1259522-B1 | LIGAND AND COMPLEX FOR CATALYTICALLY BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2003-09-10 | — | — | EP | claimed |
| US-6610641-B2 | Transition metal complex | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-08-26 | — | — | US | claimed |
| US-20020010120-A1 | Composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | claimed |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-9593232-B2 | Liquid hardening | OMG UK TECHNOLOGY LTD. (GB) | 2017-03-14 | — | — | US | disclosed |
| US-9150705-B2 | Curing liquids | OMG ADDITIVES LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9034785-B2 | Accelerator solution and process for curing curable resins | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2015-05-19 | — | — | US | disclosed |
| EP-2521750-B1 | CURING LIQUIDS | OMG UK TECHNOLOGY LTD (GB) | 2014-07-02 | — | — | EP | disclosed |
| US-6610641-B2 | Transition metal complex | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1259522-A1 | LIGAND AND COMPLEX FOR CATALYTICALLY BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6432900-B1 | ANTISOILANTS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020010120-A1 | Composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001064697-A1 | LIGAND AND COMPLEX FOR CATALYTICALLY BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FRS2, PAICS, FGF23 | EGLN1 1963/4885ALDH1A1 3761/4885POLB 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.